BRIEF-Antengene Says Malaysian National Pharmaceutical Regulatory Agency Approves Xpovio For Relapsed Or Refractory DLBCL

Reuters
Dec 17, 2025
BRIEF-Antengene Says Malaysian National Pharmaceutical Regulatory Agency Approves Xpovio For Relapsed Or Refractory DLBCL

Dec 17 (Reuters) - Antengene Corp Ltd 6996.HK:

  • MALAYSIAN NATIONAL PHARMACEUTICAL REGULATORY AGENCY APPROVES XPOVIO FOR RELAPSED OR REFRACTORY DLBCL

Further company coverage: 6996.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10